Investing in research lies at the heart of everything we do.
It’s what allows world-leading experts to investigate potential drugs, expedite new treatments and, fundamentally, work towards finding a cure for MND.
To ensure we fund only the smartest, most efficient research, we implement best practices in research management.
We award our research grants through a competitive process. We are full members of the Association of Medical Research Charities (AMRC), and we adhere to their guidelines and principles of peer review.
Our Research Review Committee oversees due diligence of our Advancing Treatments and Catalyst Awards. They are a group of independent experts including academics, clinicians, industry representatives and people affected by MND.
University of Sheffield
MSD
Affected by MND
University of Oxford
Technical University Munich
University College London
MSD
Affected by MND
University of Edinburgh
University of Sheffield
Affected by MND
King’s College London
University of Oxford
University of St Andrews
NRG Therapeutics
Mario Negri Institute IRCCS
Benevolent AI
Isomorphic Labs
Affected by MND
The University of Queensland
KU Leuven
Affected by MND
Pharmaron UK
Members of our RRC provide rapid and robust review for funding applications. They are highly engaged meaning our review process is fast and efficient. All applications are reviewed rigorously by scientific members of our RRC and members who are affected by MND. See here a guide to the review process for each of the awards in our Grant Scheme.
The Chair of the committee does not review individual applications but helps the committee to achieve consensus on which applications should be recommended for funding. They also work with the Foundation executive to assign reviewers to applications and resolve conflicts to ensure that funding decisions are fair, objective and transparent. In the event that the Chair is conflicted or unavailable, the Vice-Chair will take their place. Find out more about the our Chair and Vice Chair here.
Throughout our peer review process, information is kept strictly confidential. All reviewers must accept our conflict of interest policy before they agree to review a grant application. If an individual has a conflict of interest, they are not involved in reviewing that application and will not be involved in the panel discussion or decision-making process for that application.
We support the principle of using animals in research when there is no alternative, or when absolutely necessary to advance our understanding of motor neuron disease and potential new treatments. We are committed to the 3Rs of reduction, replacement and refinement, as basic principles of humane animal research. As members of the AMRC, we endorse their position statement on the use of animals in research.
We believe that open and transparent dissemination of knowledge resulting from research is essential to accelerate progress and avoid duplication. We encourage our researchers to disseminate research findings - both positive and negative - at conferences and other meetings. We encourage our researchers to publish their findings as rapidly as possible in peer-reviewed papers and make manuscipts open access, these costs can be covered in our grants.Publications arising from clinical trials should comply with the CONSORT Statement, and those arising from animal research should comply with the ARRIVE guidelines.
Our Discovery Network is underpinned by it's own open science policy.
Involving people affected by MND in everything we do forms an important part of our Research Strategy, to ensure their needs and priorities remain at the heart of our activities. For example, people affected by MND form an essential part of our Research Review Committee, ensuring the research we fund matters to people affected by the disease. We support AMRC’s position statement on the importance of involvement in medical research.